dividends
RP
NASDAQ · RPRX
Royalty Pharma plc
Healthcare · Biotechnology
$58.47
Down-$0.58 (-0.98%)
Updated Sep 16, 2026, 6:14 AM
SID Score
7.3/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 16.85B
- P/E ratio
- 16.44
- Dividend yield
- 1.51%
- 52-week range
- $34.63 – $64.38
- Volume
- 2.75M
- Avg. volume
- 4.22M
Price performance
RPRX price history
1M range · 20 trading sessions · Daily adjusted prices
RPRX closed at $58.47 after 20 trading sessions, down 2.04% for the selected period.
- Last close
- $58.47
- Period change
- -2.04%
- Period low
- $58.47
- Period high
- $63.96
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $59.00 | $59.20 | $57.91 | $58.47 | 2.75M |
| Sep 14, 2026 | $58.66 | $59.55 | $57.75 | $59.05 | 2.97M |
| Sep 11, 2026 | $58.95 | $59.54 | $58.35 | $58.61 | 2.6M |
| Sep 10, 2026 | $60.445 | $60.71 | $58.64 | $58.75 | 3.32M |
| Sep 9, 2026 | $60.60 | $60.80 | $59.31 | $60.59 | 4.34M |
| Sep 8, 2026 | $59.21 | $60.86 | $58.63 | $60.59 | 8.63M |
| Sep 4, 2026 | $63.55 | $64.38 | $63.43 | $63.96 | 3.4M |
| Sep 3, 2026 | $63.565 | $63.94 | $62.50 | $63.88 | 2.76M |
| Sep 2, 2026 | $62.66 | $63.285 | $62.03 | $63.11 | 3.14M |
| Sep 1, 2026 | $61.815 | $62.58 | $61.61 | $62.32 | 2.63M |
| Aug 31, 2026 | $60.805 | $61.68 | $60.39 | $61.41 | 3.9M |
| Aug 28, 2026 | $61.92 | $62.01 | $60.6553 | $60.85 | 1.7M |
| Aug 27, 2026 | $61.42 | $62.35 | $61.01 | $61.92 | 2.09M |
| Aug 26, 2026 | $62.04 | $62.28 | $61.49 | $61.80 | 1.48M |
| Aug 25, 2026 | $61.33 | $62.455 | $60.87 | $62.07 | 1.71M |
| Aug 24, 2026 | $61.19 | $61.54 | $60.8043 | $61.33 | 2.36M |
| Aug 21, 2026 | $60.53 | $61.60 | $60.37 | $61.31 | 2.33M |
| Aug 20, 2026 | $61.33 | $62.13 | $60.37 | $60.58 | 3.14M |
| Aug 19, 2026 | $60.12 | $61.80 | $59.75 | $61.73 | 3.26M |
| Aug 18, 2026 | $59.74 | $60.42 | $59.655 | $59.69 | 2.08M |
Latest RPRX news
The latest Smart Investors Daily articles mentioning RPRX.
Stock researchCompany · Overview
RPRX research
Overview
Company profile and research snapshot.
Company profile
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $47.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 8, 2026 | TD Cowen | Buy | — |
| Aug 7, 2026 | JP Morgan | Overweight | — |
| Jul 13, 2026 | TD Cowen | Buy | — |
| May 7, 2026 | JP Morgan | Overweight | — |
| May 7, 2026 | Citigroup | Buy | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.